TRANSFORMING PHYSICIAN PRESCRIBING: THE REDUCTION OF PHARMACY AND HOSPITAL COSTS IN A POPULATION OF STATE MEDICAID PATIENTS THROUGH AN AUTOMATED EDUCATIONAL INTERVENTION

Autor: John P. Docherty, George L. Oestreich, Joseph J. Parks, Jack M. Gorman, Harold Carmel, Jeffrey Veach

Publikováno v: Technology & Innovation. 15:43-51

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95ef0f27383622025cd6717475ed3dd0
https://doi.org/10.3727/194982413x13608676060538

Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease

Autor: Steven G. Potkin, Jeffrey Veach, Richard Hartman, George T. Grossberg, Ravi Anand

Publikováno v: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 26:713-720

Objectives: To investigate the relationship between activities of daily living (ADL) impairment and Alzheimer's disease (AD) severity in mild to moderately severe AD patients receiving the cholinesterase (ChE) inhibitor rivastigmine. Methods: ADLs we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc748ad91c62b03f31278092c0e87e9
https://doi.org/10.1016/s0278-5846(02)00212-9

An efficacy and safety analysis of ExelonR in Alzheimer's disease patients with concurrent vascular risk factors

Autor: John Messina, Ravi Anand, Richard Hartman, V. Kumar, Jeffrey Veach

Publikováno v: European Journal of Neurology. 7:159-169

We evaluated the efficacy and safety of the centrally acting cholinesterase inhibitor, rivastigmine tartrate, for patients with mild to moderately severe Alzheimer's disease (AD) with or without concurrent vascular risk factors (VRF). Patients (45-90

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d11c0c306e08d40a517b06727b61d528
https://doi.org/10.1046/j.1468-1331.2000.00046.x

Contents Vol. 44, 2000

Autor: Theodor Landis, P. Schnider, Nermin Mutluer, H. Kollegger, F. Chalaupka Devetag, Rei Kashima, Riki Okeda, N.C. Silver, Kenshi Kaneda, H. Warnkross, Å. Edman, A. Wallin, D.H. Miller, Hans-Jürgen von Giesen, G. Dirnberger, Gabriele Arendt, Özlem Gökdemir, L. Boscariolo, Masahito Yamada, W. Gerschlager, John Messina, M. Sjögren, G. Giovannoni, Daniel O. Slosman, Philippe Girard-Madoux, Orlando Personeni, Megumi Nakayama, Jacob Korula, Etsuko Yoshida, S.T. Engelter, K. Vass, W. Endl, R. Krause, Satoshi Orimo, K. Blennow, P.A. Lyrer, Pierre Krolak-Salmon, Richard Hartman, L. Deecke, Mikiko Uematsu, Claire Houzard, B. Regland, Sung Soo Lee, Jeffrey Veach, Bernard Croisile, Haruko Hino, Eisuke Ozawa, Natsue Shimizu, E.C. Kirsch, H. Özden Şener, Seiitsu Ono, Martin R. Farlow, W. Lang, Said R. Beydoun, Til Menge, G. Lindinger, Il Saing Choi, C.D. Good, R. Beisteiner, E.J. Thompson, Ravi Anand, Caroline Tilikete, Tobias Neumann-Haefelin, Soochul Park, Yoshiyuki Kuroiwa, Dane D. Copeland, Asako Tagawa, Yeon Kyung Jung, Alice Setiey, Ken Johkura, Alain Vighetto, E.C. Reisinger, Patrice H. Lalive, A.J. Steck, Pierre R. Burkhard, Atsushi Komiyama, Hidehiro Mizusawa

Publikováno v: European Neurology. 44:263-265

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72fcb5a4f14cd11afff66cc3dfdf5aa4
https://doi.org/10.1159/000008255

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

Autor: P Murali, Doraiswamy, K Ranga Rama, Krishnan, Ravi, Anand, Hyesung, Sohn, Jacquiline, Danyluk, Richard D, Hartman, Jeffrey, Veach

Publikováno v: Progress in neuro-psychopharmacologybiological psychiatry. 26(4)

Goals of the study included evaluating the long-term efficacy of rivastigmine in Alzheimer's disease (AD) patient categories stratified by baseline dementia severity, and post hoc investigation of particular benefits of early initiation of rivastigmi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::21acd240051740939071a2784fc88bb1
https://pubmed.ncbi.nlm.nih.gov/12188103